Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
November 01 2023 - 8:32AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO SECTION 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2023
Commission File Number: 001-41316
Alpha Tau Medical
Ltd.
(Exact Name of Registrant as Specified in Its Charter)
Kiryat HaMada St. 5
Jerusalem, Israel 9777605
+972 (3) 577-4115
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
CONTENTS
On November 1, 2023, Alpha Tau Medical Ltd. (the “Company”)
issued a press release titled “Alpha Tau to Participate in November Investor Conferences.” A copy of this press release is
attached to this Form 6-K as Exhibit 99.1.
The information in this Report on Form 6-K, including
in Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall
it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange
Act, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Alpha Tau Medical Ltd. |
|
|
|
Date: November 1, 2023 |
By: |
/s/ Uzi Sofer |
|
|
Uzi Sofer |
|
|
Chief Executive Officer |
3
Exhibit 99.1
Alpha Tau to
Participate in November Investor Conferences
JERUSALEM, November 1, 2023 (GLOBENEWSWIRE) -- Alpha Tau Medical Ltd.
(“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy
Alpha DaRT™, today announced that management will participate in the following investor conferences
in November 2023.
Event: |
Emerging
Growth Conference |
Format: |
Company
presentation and 1-on-1 meetings |
Date: |
Thursday,
November 2nd, 2023 |
Time |
3:25
– 3:35 PM ET |
Location: |
Virtual |
Event: |
Jefferies
London Healthcare Conference |
Format: |
Company
presentation and 1-on-1 meetings |
Date: |
Wednesday,
November 15th, 2023 |
Time: |
10:00
AM GMT |
Location: |
London |
Event: |
Piper
Sandler 35th Annual Healthcare Conference |
Format: |
Fireside
chat and 1-on-1 meetings |
Date: |
Tuesday,
November 28th, 2023 |
Time: |
11:30
AM ET |
Location: |
New
York, NY |
Please
reach out to your Jefferies and Piper Sandler representatives to schedule, and register here to ensure you are able to attend the Emerging
Growth conference and receive any updates that are released. https://goto.webcasts.com/starthere.jsp?ei=1603286&tp_key=f701725cb0&sti=drts
If attendees
are not able to join the event live on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com
and on the Emerging Growth YouTube Channel, http://www.YouTube.com/EmergingGrowthConference.
About Alpha Tau Medical Ltd.
Founded in 2016,
Alpha Tau is an Israeli medical device company that focuses on research, development, and potential commercialization of the Alpha DaRT
for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv
University.
About Alpha DaRT™
Alpha DaRT (Diffusing Alpha-emitters Radiation
Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated
sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha
particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly
affect the tumor, and to spare the healthy tissue around it.
Investor Relations Contact:
IR@alphatau.com
Alpha Tau Medical (NASDAQ:DRTS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Alpha Tau Medical (NASDAQ:DRTS)
Historical Stock Chart
From Jul 2023 to Jul 2024